Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KNTE
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Kinnate Biopharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 124.99M
- Ent value
- 82.27M
- Price/Sales
- -
- Price/Book
- 0.78
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -57.60%
- 3 year return
- -56.02%
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
KNTE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.78 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 47.17M |
| EPS (TTM) | -2.35 |
| FCF per share (TTM) | -2.12 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -799.00K |
| Operating income (TTM) | -120.98M |
| Net income (TTM) | -110.94M |
| EPS (TTM) | -2.35 |
| EPS (1y forward) | -1.04 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 57.00M |
| Net receivables | 0.00 |
| Total current assets | 158.18M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 6.30M |
| Total assets | 173.60M |
| Accounts payable | 2.03M |
| Short/Current long term debt | 3.17M |
| Total current liabilities | 11.99M |
| Total liabilities | 14.28M |
| Shareholder's equity | 159.33M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -100.04M |
| Capital expenditures (TTM) | 18.00K |
| Free cash flow (TTM) | -100.06M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -69.63% |
| Return on Assets | -63.90% |
| Return on Invested Capital | -69.24% |
| Cash Return on Invested Capital | -62.45% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| KNTE | S&P500 | |
| Current price drop from All-time high | -94.14% | -0.72% |
| Highest price drop | -97.64% | -56.47% |
| Date of highest drop | 27 Oct 2023 | 9 Mar 2009 |
| Avg drop from high | -71.22% | -11.07% |
| Avg time to new high | 279 days | 12 days |
| Max time to new high | 833 days | 1805 days |
COMPANY DETAILS
Marketcap
124.99M
Marketcap category
Small-cap
Description
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Employees
84
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner